No Data
Tianjin Lisheng Pharmaceutical Reports Lower January-September Profit
Lisheng Pharmaceuticals: Report for the third quarter of 2024
tianjin lisheng pharmaceutical (002393.SZ) released its performance for the first three quarters, with a net income of 0.169 billion yuan, a year-on-year decrease of 50.61%.
In the third quarter of 2024, Tianjin Lisheng Pharmaceutical (002393.SZ) released its quarterly report, achieving revenue in the first three quarters...
Lisheng Pharmaceutical Gets API Approval in China for Apremilast
Tianjin Lisheng Pharmaceutical (002393.SZ): The chemical raw material active pharmaceutical ingredient Apmisartan has passed the marketing authorization application.
On October 17, Lisheng Pharmaceutical (002393.SZ) announced that Tianjin Lisheng Pharmaceutical Co., Ltd. recently received the National Medical Products Administration's issued Approval Letter for the listing application of apremilast active pharmaceutical ingredient (referred to as "the API") for chemical raw materials (Approval Letter No.: 2024YS00982). The API has passed the domestic production application for chemical raw materials. The main variety mainly inhibits the synthesis of phosphodiesterase 4, increases the content of intracellular cyclic adenosine monophosphate, thereby exerting an anti-inflammatory effect. Clinically used to treat those who meet the indications for phototherapy or systemic therapy.
Tianjin Lisheng Pharmaceutical Co.,Ltd.'s (SZSE:002393) Stock Is Going Strong: Have Financials A Role To Play?
Investors Don't See Light At End Of Tianjin Lisheng Pharmaceutical Co.,Ltd.'s (SZSE:002393) Tunnel And Push Stock Down 25%
No Data
